Johnson & Johnson reported mixed quarterly results with reported sales slightly below last year but strong operational growth. Management provided optimistic guidance for 2016, exceeding analyst expectations and emphasizing strategic investments and innovation. The positive outlook is likely to bolster investor confidence in the short term.

[1]